Hypoparathyroidism

Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This can lead to low levels of calcium in the blood, often causing cramping and twitching of muscles or tetany (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The diagnosis is made with blood tests, and other investigations such as genetic testing depending on the results. The treatment of hypoparathyroidism is limited by the fact that there is no artificial form of the hormone that can be administered as replacement; calcium replacement or vitamin D can ameliorate the symptoms but can increase the risk of kidney stones and chronic kidney disease.

Signs and symptoms

The main symptoms of hypoparathyroidism are the result of the low blood calcium level, which interferes with normal muscle contraction and nerve conduction. As a result, people with hypoparathyroidism can experience paresthesia, an unpleasant tingling sensation around the mouth and in the hands and feet, as well as muscle cramps and severe spasms known as "tetany" that affect the hands and feet. Many also report a number of subjective symptoms such as fatigue, headaches, bone pain and insomnia. Crampy abdominal pain may occur.Physical examination of someone with hypocalcemia may show tetany, but it is also possible to provoke tetany of the facial muscles by tapping on the facial nerve (a phenomenon known as Chvostek's sign) or by using the cuff of a sphygmomanometer to temporarily obstruct the blood flow to the arm (a phenomenon known as Trousseau's sign of latent tetany).

Podcasts:

PLAYLIST TIME:

Latest News for: hypoparathyroidism

Edit

Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial

Pharmiweb 17 Mar 2025
Hypoparathyroidism ... CALYPSO is a global Phase III, randomised, double-blind, placebo-controlled, multicentre trial designed to evaluate the efficacy and safety of eneboparatide in adults with chronic hypoparathyroidism.
Edit

Eneboparatide met primary endpoint of normalizing serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial (AstraZeneca Pharmaceuticals LP)

Public Technologies 17 Mar 2025
Hypoparathyroidism ... CALYPSO is a global Phase III, randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy and safety of eneboparatide in adults with chronic hypoparathyroidism ... Hypoparathyroidism.
Edit

Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial (Form 6-K) (AstraZeneca plc)

Public Technologies 17 Mar 2025
Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial ... Hypoparathyroidism ... Hypoparathyroidism ... A population-based study of the epidemiology of chronic hypoparathyroidism.
Edit

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

Nasdaq Globe Newswire 03 Mar 2025
AvailTM trial exceeded enrollment target; topline results expected in Q3 2025. AvailTM trial exceeded enrollment target; topline results expected in Q3 2025 ... .
  • 1
×